Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany
{{output}}
Background: Monoclonal antibodies (mAbs) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway are safe and effective treatments for migraine prevention. However, the high cost of these novel therapies has led to reimburse... ...
